Want to see PHG full AI Analyst Report?
Koninklijke Philips (PHG) AI Stock Analysis
Koninklijke Philips
(NYSE:PHG)
Philips' overall score is driven by its robust return to profitability, an attractive 3.75% dividend yield, and positive operational momentum in its Personal Health segment. Short-term technical indicators show promising bullish momentum, though long-term resistance remains. The score is notably constrained by execution risks surrounding a back-end-loaded Q4 margin recovery, ongoing demand challenges in the Chinese market, and rising balance sheet leverage.
Koninklijke Philips Key Performance Indicators (KPIs)
Koninklijke Philips (PHG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $26.17B
- Dividend Yield
- 3.68%
- Average Volume (3M)
- 966.00K
- Price to Earnings (P/E)
- 20.7
- Beta (1Y)
- 0.96
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 66,401
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Koninklijke Philips Business Overview & Revenue Model
Company Description
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis...
How the Company Makes Money
Philips makes money primarily by selling healthcare equipment, software, and related services to hospitals, clinics, and other healthcare providers, supplemented by revenue from certain consumer health/personal health offerings. Key revenue streams i...
Koninklijke Philips Earnings Call Summary
The call conveyed a generally positive operational and financial tone: key growth metrics (comparable sales ~4%), strong order momentum (rolling 12‑month +5%), record equipment order book, robust Personal Health performance, notable commercial wins and continued productivity delivery supported the narrative. However, meaningful near‑term headwinds remain — elevated cost inflation, China centralized procurement pressure, D&T margin weakness ex‑refund, and timing/phasing of large cloud/platform deals — some of which depress near‑term underlying margins and introduce execution risk for the back‑loaded margin recovery. On balance, the positives (growth, order book, productivity progress, balance‑sheet improvement and reiterated guidance) outweigh the lowlights, but management highlighted areas requiring continued execution.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Philips reiterated full‑year guidance for comparable sales growth of 3.0–4.5% and an underlying (ex‑tariff refund) adjusted EBITA margin target of 12.5–13.0% (13.5–14.0% including the Q2 tariff refund); in Q2 comparable sales rose ~4%, adjusted EBITA margin was 16.4% including the refund and 12.2% excluding it, and Q2 free cash flow was EUR 222m. The company now expects reported full‑year free cash flow of EUR 1.5–1.7bn (underlying EUR 1.3–1.5bn excluding the refund), received virtually all of the tariff refund (including ~EUR 25m related to annual incentive accruals), and said Q3 comparable sales should be at the lower end of the full‑year range with Q3 adjusted EBITA margin below prior year while anticipating a meaningful Q4 step‑up into the upper end of the mid‑teens. Orders were resilient (rolling 12‑month intake +5%; Q2 intake -1%) and the equipment order book is at a record level; productivity delivered EUR 132m in Q2 (EUR 258m YTD) toward a EUR 1.5bn three‑year target. Balance‑sheet metrics: cash EUR 1.8bn, net debt EUR 5.7bn, leverage 1.8x (down from 2.2x), and Philips continues to assume high single‑digit cost inflation for 2026.
Koninklijke Philips Financial Statement Overview
Summary
Philips has achieved a significant turnaround by returning to net profitability and expanding gross margins above 45%. However, the score is weighed down by stagnant top-line revenue, rising leverage with a debt-to-equity ratio of 0.74, and weakened cash flow generation compared to the prior year.
Income Statement
78PositiveBalance Sheet
55NeutralCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.66B | 17.83B | 18.02B | 18.17B | 17.83B | 17.16B |
| Gross Profit | 8.11B | 8.06B | 7.77B | 7.45B | 7.19B | 7.17B |
| EBITDA | 3.05B | 2.64B | 1.85B | 1.04B | 115.00M | 2.00B |
| Net Income | 1.11B | 895.00M | -702.00M | -466.00M | -1.61B | 3.32B |
Balance Sheet | ||||||
| Total Assets | 26.70B | 26.94B | 28.98B | 29.41B | 30.69B | 30.96B |
| Cash, Cash Equivalents and Short-Term Investments | 1.79B | 2.79B | 2.40B | 1.87B | 1.18B | 2.31B |
| Total Debt | 7.46B | 8.09B | 7.49B | 7.29B | 7.34B | 6.05B |
| Total Liabilities | 15.22B | 15.96B | 16.93B | 17.34B | 17.41B | 16.49B |
| Stockholders Equity | 11.45B | 10.96B | 12.01B | 12.03B | 13.25B | 14.44B |
Cash Flow | ||||||
| Free Cash Flow | 1.90B | 893.00M | 1.35B | 1.94B | -648.45M | 1.46B |
| Operating Cash Flow | 2.29B | 1.16B | 1.70B | 2.31B | -181.82M | 1.93B |
| Investing Cash Flow | -785.68M | -737.00M | -633.87M | -553.53M | -1.58B | -317.95M |
| Financing Cash Flow | -1.57B | 107.00M | -536.52M | -916.79M | 525.49M | -2.77B |
Koninklijke Philips Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHG, the sentiment is Positive. The current price of 27.41 is above the 20-day moving average (MA) of 25.61, above the 50-day MA of 25.52, and above the 200-day MA of 26.84, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 65.39 is Neutral, neither overbought nor oversold. The STOCH value of 84.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHG.
Koninklijke Philips Peers Comparison
Overall Rating
EW81Outperform
MDT74Outperform
GEHC71Outperform
PHG70Outperform
ABT69Neutral
BSX68Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $53.03B | 52.88 | 9.69% | ― | 14.55% | 15.09% | |
| 74Outperform | $123.49B | 23.60 | 10.60% | 2.96% | 9.77% | 12.28% | |
| 71Outperform | $34.62B | 19.84 | 16.13% | 0.19% | 6.87% | -2.26% | |
| 70Outperform | $26.31B | 20.72 | 10.05% | 3.68% | ― | ― | |
| 69Neutral | $183.77B | 39.33 | 9.12% | 2.37% | 10.00% | ― | |
| 68Neutral | $60.84B | 17.71 | 14.18% | ― | 8.88% | 25.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PHG | Koninklijke Philips N.V. | 26.92 | -0.21 | -0.76% | |
| ABT | Abbott Laboratories | 106.20 | -16.55 | -13.48% | |
| BSX | Boston Scientific | 41.98 | -56.86 | -57.53% | |
| EW | Edwards Lifesciences Corp. | 92.01 | 7.86 | 9.34% | |
| MDT | Medtronic | 96.54 | 9.02 | 10.31% | |
| GEHC | Ge Healthcare Technologies Inc. | 76.57 | 2.42 | 3.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026